Botwright S, Sutawong J, Kingkaew P, Anothaisintawee T, Dabak S, Suwanpanich C
BMC Public Health. 2023; 23(1):382.
PMID: 36823618
PMC: 9948368.
DOI: 10.1186/s12889-023-15152-6.
Hyland C, McDowell M, Bain P, Huskamp H, Busch A
J Subst Abuse Treat. 2022; 144:108919.
PMID: 36332528
PMC: 10321472.
DOI: 10.1016/j.jsat.2022.108919.
Thompson S, Gianessi C, OMalley S, Cavallo D, Shi J, Tetrault J
Front Psychiatry. 2021; 12:709559.
PMID: 34531767
PMC: 8438169.
DOI: 10.3389/fpsyt.2021.709559.
Srivastava A, Clarke S, Hardy K, Kahan M
Addict Sci Clin Pract. 2021; 16(1):34.
PMID: 34034821
PMC: 8152083.
DOI: 10.1186/s13722-021-00240-y.
Antonsen K, Klausen M, Brunchmann A, Le Dous N, Jensen M, Miskowiak K
BMJ Open. 2018; 8(7):e019562.
PMID: 30012779
PMC: 6082448.
DOI: 10.1136/bmjopen-2017-019562.
Glyoxalase 1 (GLO1) Inhibition or Genetic Overexpression Does Not Alter Ethanol's Locomotor Effects: Implications for GLO1 as a Therapeutic Target in Alcohol Use Disorders.
Barkley-Levenson A, Lagarda F, Palmer A
Alcohol Clin Exp Res. 2018; 42(5):869-878.
PMID: 29532486
PMC: 5915917.
DOI: 10.1111/acer.13623.
Systematic Review of Combined Pharmacotherapy for the Treatment of Alcohol Use Disorder in Patients Without Comorbid Conditions.
Naglich A, Lin A, Wakhlu S, Adinoff B
CNS Drugs. 2017; 32(1):13-31.
PMID: 29273901
DOI: 10.1007/s40263-017-0484-2.
The overlap between binge eating disorder and substance use disorders: Diagnosis and neurobiology.
Schreiber L, Odlaug B, Grant J
J Behav Addict. 2014; 2(4):191-8.
PMID: 25215200
PMC: 4154572.
DOI: 10.1556/JBA.2.2013.015.
A Bayesian mixed-treatment comparison meta-analysis of treatments for alcohol dependence and implications for planning future trials.
DeSantis S, Zhu H
Med Decis Making. 2014; 34(7):899-910.
PMID: 24935915
PMC: 4318856.
DOI: 10.1177/0272989X14537558.
Adjunctive aripiprazole therapy with escitalopram in patients with co-morbid major depressive disorder and alcohol dependence: clinical and neuroimaging evidence.
Han D, Kim S, Choi J, Min K, Renshaw P
J Psychopharmacol. 2013; 27(3):282-91.
PMID: 23325372
PMC: 4651436.
DOI: 10.1177/0269881112472563.
Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?.
Maisel N, Blodgett J, Wilbourne P, Humphreys K, Finney J
Addiction. 2012; 108(2):275-93.
PMID: 23075288
PMC: 3970823.
DOI: 10.1111/j.1360-0443.2012.04054.x.
Long-lasting alterations in membrane properties, k(+) currents, and glutamatergic synaptic currents of nucleus accumbens medium spiny neurons in a rat model of alcohol dependence.
Marty V, Spigelman I
Front Neurosci. 2012; 6:86.
PMID: 22701402
PMC: 3370662.
DOI: 10.3389/fnins.2012.00086.
Barriers to use of pharmacotherapy for addiction disorders and how to overcome them.
Oliva E, Maisel N, Gordon A, Harris A
Curr Psychiatry Rep. 2011; 13(5):374-81.
PMID: 21773951
PMC: 4403628.
DOI: 10.1007/s11920-011-0222-2.
Glutamatergic medications for the treatment of drug and behavioral addictions.
Olive M, Cleva R, Kalivas P, Malcolm R
Pharmacol Biochem Behav. 2011; 100(4):801-10.
PMID: 21536062
PMC: 3154511.
DOI: 10.1016/j.pbb.2011.04.015.
Comparison of healthcare utilization among patients treated with alcoholism medications.
Mark T, Montejano L, Kranzler H, Chalk M, Gastfriend D
Am J Manag Care. 2011; 16(12):879-88.
PMID: 21348558
PMC: 4160801.
How confident should we be that smoking cessation treatments work?.
Hughes J
Addiction. 2009; 104(10):1637-40.
PMID: 19681807
PMC: 2888616.
DOI: 10.1111/j.1360-0443.2009.02645.x.
Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary.
Blum K, Chuan Chen A, Chen T, Braverman E, Reinking J, Blum S
Theor Biol Med Model. 2008; 5:24.
PMID: 19014506
PMC: 2615745.
DOI: 10.1186/1742-4682-5-24.